See more : Perpetual Equity Investment Company Limited (PIC.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Alaunos Therapeutics, Inc. (TCRT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alaunos Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- National Medical Care Company (4005.SR) Income Statement Analysis – Financial Results
- Sanoma Oyj (SAA1V.HE) Income Statement Analysis – Financial Results
- The Hershey Company (0J4X.L) Income Statement Analysis – Financial Results
- Kingland Technology Co.,Ltd. (000711.SZ) Income Statement Analysis – Financial Results
- BioRestorative Therapies, Inc. (BRTX) Income Statement Analysis – Financial Results
Alaunos Therapeutics, Inc. (TCRT)
About Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.00K | 2.92M | 398.00K | 0.00 | 0.00 | 146.00K | 6.39M | 6.86M | 4.33M | 1.37M | 800.00K | 800.00K | 667.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.57K | 1.73K |
| Cost of Revenue | 4.80M | 2.76M | 740.00K | 1.13M | 629.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -4.80M | 163.00K | -342.00K | -1.13M | -629.00K | 146.00K | 6.39M | 6.86M | 4.33M | 1.37M | 800.00K | 800.00K | 667.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.57K | 1.73K |
| Gross Profit Ratio | -95,960.00% | 5.58% | -85.93% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 16.28M | 25.02M | 49.64M | 52.70M | 38.33M | 34.13M | 45.08M | 157.79M | 106.79M | 32.71M | 42.85M | 83.45M | 57.08M | 12.91M | 4.56M | 17.25M | 18.99M | 10.39M | 5.59M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 12.22M | 13.14M | 27.56M | 27.67M | 19.53M | 19.92M | 14.80M | 14.38M | 17.65M | 12.17M | 15.66M | 19.52M | 14.98M | 11.64M | 7.57M | 8.37M | 773.14K | 8.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 120.00 |
| SG&A | 12.22M | 13.14M | 27.56M | 27.67M | 19.53M | 19.92M | 14.80M | 14.38M | 17.65M | 12.17M | 15.66M | 19.52M | 14.98M | 11.64M | 7.57M | 8.37M | 9.58M | 8.72M | 4.19M | 39.17K | 35.36K | 0.00 | 120.00 |
| Other Expenses | 971.00K | 529.00K | -1.20M | 385.00K | 813.00K | 631.00K | 465.00K | 134.00K | 12.00K | -5.00K | -579.00K | -13.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.39M | 0.00 | 0.00 | 486.00 | 42.51K | 74.14K |
| Operating Expenses | 29.47M | 38.16M | 77.21M | 80.36M | 57.86M | 54.05M | 59.88M | 172.17M | 124.43M | 44.87M | 58.51M | 102.97M | 72.07M | 24.55M | 12.12M | 25.62M | 28.57M | 19.11M | 9.79M | 39.17K | 35.84K | 42.51K | 74.26K |
| Cost & Expenses | 34.27M | 38.16M | 77.21M | 80.36M | 57.86M | 54.05M | 59.88M | 172.17M | 124.43M | 44.87M | 58.51M | 102.97M | 72.07M | 24.55M | 12.12M | 25.62M | 28.57M | 19.11M | 9.79M | 39.17K | 35.84K | 42.51K | 74.26K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 388.00K | 1.96M | 1.25M | 270.48K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.92M | 3.15M | 1.18M | 0.00 | 0.00 | 0.00 | 830.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.12M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.32M | 2.76M | 2.60M | 1.13M | 629.00K | 573.00K | 369.00K | 290.00K | 357.00K | 462.00K | 738.00K | 658.00K | 268.00K | 188.00K | 330.00K | 388.00K | 433.35K | 173.92K | 101.23K | 0.00 | 486.00 | 799.00 | 750.00 |
| EBITDA | -30.90M | -31.82M | -74.97M | -78.85M | -117.17M | -53.33M | -53.12M | -165.01M | -119.73M | -43.50M | -56.98M | -102.17M | -71.40M | -32.48M | -7.32M | -24.84M | -26.17M | -17.68M | -9.42M | -5.65M | -35.36K | -39.14K | -71.79K |
| EBITDA Ratio | -618,080.00% | -1,187.85% | -19,112.81% | 0.00% | 0.00% | -37,030.14% | -817.00% | -2,407.56% | -2,772.39% | -4,022.00% | -7,270.00% | -13,445.13% | -11,807.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,523.04% | -4,159.04% |
| Operating Income | -34.27M | -35.11M | -77.55M | -80.36M | 2.26M | -53.91M | -53.49M | -165.31M | -120.10M | -43.50M | -57.71M | -102.17M | -71.40M | -24.55M | -12.12M | -25.62M | -28.57M | -19.11M | -9.79M | -39.17K | -35.84K | -39.94K | -72.54K |
| Operating Income Ratio | -685,340.00% | -1,201.40% | -19,484.67% | 0.00% | 0.00% | -36,921.92% | -837.27% | -2,409.37% | -2,772.39% | -3,168.17% | -7,214.13% | -12,771.13% | -10,704.65% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,554.12% | -4,202.49% |
| Total Other Income/Expenses | -873.00K | -2.63M | -1.20M | 385.00K | -59.94M | 789.00K | -830.00K | 10.00K | 12.00K | 11.72M | 606.00K | 6.04M | 7.62M | -8.12M | 4.47M | 388.00K | 1.96M | 1.25M | 270.48K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -35.14M | -37.73M | -78.75M | -79.98M | -117.80M | -53.12M | -54.32M | -165.30M | -120.09M | -31.78M | -57.11M | -96.13M | -63.78M | -32.67M | -7.65M | -25.23M | 0.00 | -17.86M | 0.00 | -39.17K | -35.84K | -39.94K | -72.54K |
| Income Before Tax Ratio | -702,800.00% | -1,291.24% | -19,786.68% | 0.00% | 0.00% | -36,381.51% | -850.26% | -2,409.23% | -2,772.11% | -2,314.71% | -7,138.38% | -12,016.50% | -9,561.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,554.12% | -4,202.49% |
| Income Tax Expense | 0.00 | -133.00K | -1.86M | -1.13M | 60.12M | -947.00K | 2.13M | 114.00K | -12.00K | -23.44M | -1.79M | -12.09M | -15.24M | 16.25M | -8.95M | -388.00K | -1.96M | -1.25M | -270.48K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -35.14M | -37.60M | -76.89M | -78.85M | -177.92M | -53.12M | -54.32M | -165.30M | -120.09M | -31.78M | -57.11M | -96.13M | -63.78M | -32.67M | -7.65M | -25.23M | -26.61M | -17.86M | -9.52M | -39.17K | -35.84K | -39.94K | -72.54K |
| Net Income Ratio | -702,800.00% | -1,286.69% | -19,320.10% | 0.00% | 0.00% | -36,381.51% | -850.26% | -2,409.23% | -2,772.11% | -2,314.71% | -7,138.38% | -12,016.50% | -9,561.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,554.12% | -4,202.49% |
| EPS | -21.97 | -25.97 | -53.80 | -56.42 | -158.90 | -55.52 | -59.50 | -190.15 | -143.63 | -47.14 | -99.67 | -183.58 | -144.94 | -106.52 | -49.65 | -178.25 | -211.94 | -213.06 | -262.83 | -39.44 | -18.31 | -26.73 | -48.55 |
| EPS Diluted | -21.97 | -25.97 | -53.80 | -56.42 | -158.90 | -55.44 | -59.50 | -190.15 | -143.63 | -47.14 | -99.67 | -183.58 | -144.94 | -106.52 | -49.65 | -178.25 | -211.94 | -213.06 | -262.83 | -39.44 | -18.31 | -26.73 | -48.55 |
| Weighted Avg Shares Out | 1.60M | 1.45M | 1.43M | 1.40M | 1.12M | 956.72K | 912.92K | 869.28K | 836.11K | 674.20K | 572.95K | 523.64K | 440.03K | 306.69K | 154.05K | 141.55K | 125.55K | 83.81K | 36.21K | 993.00 | 1.96K | 1.49K | 1.49K |
| Weighted Avg Shares Out (Dil) | 1.60M | 1.45M | 1.43M | 1.40M | 1.12M | 958.07K | 912.92K | 869.28K | 836.11K | 674.20K | 572.95K | 523.64K | 440.03K | 306.69K | 154.05K | 141.55K | 125.55K | 83.81K | 36.21K | 993.00 | 1.96K | 1.49K | 1.49K |
Penny Stocks With Huge Potential According To 4 Wall Street Analysts
Penny stocks with huge potential according to analysts in 2022. The post Penny Stocks With Huge Potential According To 4 Wall Street Analysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
What Makes Ziopharm (TCRT) a New Buy Stock
Ziopharm (TCRT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Penny Stocks To Buy? 8 Short Squeeze Stocks To Watch Now
Short squeeze penny stocks to watch. The post Penny Stocks To Buy?
Alaunos Therapeutics, Inc. (TCRT) Kevin Boyle on Q4 2021 Results - Earnings Call Transcript
Alaunos Therapeutics, Inc. (TCRT) Kevin Boyle on Q4 2021 Results - Earnings Call Transcript
Alaunos Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 30, 2022
HOUSTON, March 16, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the fourth quarter ended December 31, 2021 on Wednesday, March 30, 2022, before the open...
Source: https://incomestatements.info
Category: Stock Reports